《盈警響號》金斯瑞生物科技(01548.HK)料中期虧損約2.03億至2.38億美元
金斯瑞生物科技(01548.HK)發盈警,預期截至2022年6月30日止六個月錄得虧損約2.03億美元至2.38億美元,而2021年同期錄得虧損約1.56億美元;預期錄得經調整虧損約1.15億美元至1.37億美元,而2021年同期錄得經調整虧損約1.36億美元。
經調整虧損不包括以股權結算的股份薪酬開支、匯兌損益、因調查產生的諮詢費和其他相關成本、金融負債的公允價值虧損、非流動金融資產的公允價值損益,及公開發售服務費。
集團表示,除細胞療法業務之外的集團業務的經調整淨利潤保持穩定增長,預期增長約10.3%至20.9%。非細胞療法業務預期錄得經調整淨利潤約2,900萬美元至3,180萬美元,而2021年同期約為2,630萬美元,主要源自集團CDMO及合成生物學業務盈利能力的持續提升。
集團非全資附屬附屬傳奇生物(LEGN.US)投資細胞療法業務預期錄得經調整虧損約1.45億美元至1.69億美元,主要來自研發開支約1.35億美元至1.58億美元,主要是由於持續投資其主打候選產品西達基奧侖賽及其他潛在候選產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.